Publications

Zhang et al. observed that, compared to the control group, ixekizumab was associated with an increased risk of new-onset IBD in psoriasis patients, and that there is insufficient evidence to confirm that ustekinumab, bimekizumab, secukinumab, and brodalumab significantly increase the risk of new-onset IBD. Zhang et al. evaluated the risk of new-onset IBD in psoriasis patients treated with five IL inhibitors (bimekizumab, ixekizumab, secukinumab, brodalumab, and ustekinumab), providing insights to inform clinical decision-making. Additionally, compared to the control group, no significant difference was observed in the risk of diarrhoea as an AE.

Since RA patients are at an increased risk of a CV event, there have been several studies to determine if RA treatments alter this risk. In a retrospective study, Zhang and colleagues assess the risk of CV events in patients initiating bDMARDs.Using Medicare medical and pharmacy claims data, the incidence rate (IR) of acute myocardial infarction (AMI) and of a composite CHD* was calculated across RA patients initiating 8 different biologics: ABA, ADA, CER, ETA, GOL, INF, RIT, and TOC. There were...